DDInter478 DDInter875
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296]
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Daratumumab may lead to a major life threatening interaction when taken with Cladribine
Daratumumab may lead to a major life threatening interaction when taken with Rotavirus vaccine